IMDX
Insight Molecular Diagnostics Inc.
NASDAQ · USHealthcareBiotechnology
$4.84+2.11%
Price as of Jul 20, 2026
IMDX profitability
Insight Molecular Diagnostics Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 19.5%
- EBITDA margin
- -2329.5%
- EBIT margin
- -2112.4%
- Net margin
- -2454.6%
- Free cash flow margin
- -1408.7%
Returns
- Return on equity
- 447.5%
- Return on assets
- -118.3%
- Return on invested capital
- 540.2%
- Asset turnover
- 0.06x
Cash efficiency
- Cash from operations
- -$24.0M
- Cash per share
- $0.87
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.